All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

After ASH 2022, are we closer to using MRD-guided treatment decisions in MM?

Featured
Dec 21, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new development in the monitoring of multiple myeloma.

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Benjamin Derman, University of Chicago, Chicago, US. We asked, After ASH 2022, are we closer to using minimal residual disease (MRD)-guided treatment decisions in multiple myeloma (MM)?

After ASH 2022, are we closer to using MRD-guided treatment decisions in MM?

Derman opens by discussing the results of trials presented in ASH abstracts14 that consider the theme of MRD-guided de‑escalation of therapy, with a focus on the proportion of patients who remained off-treatment after de-escalation of maintenance therapy, as well as the number with resurgence and progression. Derman concludes by explaining how these combined results allow for better identification of patients who can safely discontinue treatment after an extended period of maintenance therapy and sustained MRD negativity.

  1. Megala Costa LJ, Chhabra S, Medvedova E, et al. Outcomes of MRD-adapted treatment modulation in patients with newly diagnosed multiple myeloma receiving daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) and autologous transplantation: Extended follow up of the Master trial. Poster #3237. Presented at: 64th American Society of Hematology Annual Meeting and Exposition; Dec 11, 2022; New Orleans, US.
  2. Norde K, Diamond B, Burge M, et al. Maintenance therapy cessation for sustained MRD negative multiple myeloma patients. Oral abstract #992. Presented at: 64th American Society of Hematology Annual Meeting and Exposition; Dec 12, 2022; New Orleans, US.
  3. Sweiss K, Hofmeister CC, Zappia M, et al. Free from maintenance drug therapy in multiple myeloma (the FREEDMM trial): A pilot study of minimal residual disease (MRD)-driven discontinuation of maintenance. Poster #3247. Presented at: 64th American Society of Hematology Annual Meeting and Exposition; Dec 11, 2022; New Orleans, US.
  4. Derman BA, Major A, Major S, et al.. Prospective trial using multimodal measurable residual disease negativity to guide discontinuation of maintenance therapy in multiple myeloma (MRD2STOP). Oral abstract #870. Presented at: 64th American Society of Hematology Annual Meeting and Exposition; Dec 12, 2022; New Orleans, US.